Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
1999-06-30
2001-11-27
Chin, Christopher L. (Department: 1641)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C424S093100, C424S152100, C424S130100, C424S178100, C424S184100, C424S094100, C424S085100, C424S277100, C435S004000, C435S005000, C435S007800, C435S006120, C435S007100, C435S007210, C435S014000, C435S070100, C435S046000, C435S287300, C435S325000, C435S289100, C436S500000, C436S806000, C436S095000, C436S169000, C436S120000, C436S808000, C436S805000, C436S170000, C436S119000, C436S817000, C436S169000, C436S153000, C530S387100
Reexamination Certificate
active
06323321
ABSTRACT:
BACKGROUND OF THE INVENTION
1. Field of the Invention
The invention relates to a monoclonal antibody which binds to an antigen on the megakaryocytic cell line UT-7.
Antibodies of this kind are generally known.
2. Description of the Related Art
Until now, diagnostic analyses have been carried out either microscopically according to cell morphology after staining with classical staining methods, for example staining according to Pappenheim, and by manually counting. In modern methods for analysis of bone marrow biopsies or blood samples antibodies detecting specific antigens as markers for specific cell types and cell stages are used. The recognized antigens can be detected automatically using standard methods like EEISA (enzyme linked immunosorbent assay) or flow cytometry (FACS analysis, fluorescence activated cell sorting) in an automatic manner. Adequate antibodies having a high sensitivity and above all specificity for the different cell types and cell stages and additionally being available in large amounts are essential for the application of these kinds of methods.
SUMMARY OF THE INVENTION
It is, therefore, an object of the present invention to provide an antibody detecting an antigen on the megakaryocytic cell line UT-7 and being available in practically unlimited amounts.
The object is achieved by providing a monoclonal antibody produced and released by hybridoma cells deposited under No. DSM ACC2297 on Feb. 12, 1997, at “Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH (DSMZ)”, the German Collection of Microorganisms and Cell Cultures Ltd. Mascheroder Weg 1b, D-38124 Braunschweig, Germany, under the provision of the Budapest Treaty, that all restrictions upon public access to the deposit will be irrevocably removed upon the grant of a patent on this application and that the deposit will be replaced if viable samples cannot be dispensed by the depository. The antibody is designated 97A6.
The invention also relates to hybridoma cells that have been deposited under No. DSM ACC2297 at “Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH (DSMZ)”, the German Collection of Microorganisms and Cell Cultures Ltd., Mascheroder Weg 1b, D-38124 Braunschweig, Germany, under the provision of the Budapest Treaty, that all restrictions upon public access to the deposit will be irrevocably removed upon the grant of a patent on this application and that the deposit will be replaced if viable samples cannot be dispensed by the depository producing the antibody having the designation 97A6.
In order to facilitate the application of the antibody according to the invention, the antibody can be mixed with adequate auxiliary substances in a pharmaceutical composition. Consequently, the invention also relates to a pharmaceutical agent, comprising the antibody according to the invention. Preferably, this pharmaceutical agent comprises the antibody produced and secreted by hybridoma cells deposited under No. DSM ACC2297 at the “Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH, DSMZ”, the German Collection of Microorganisms and Cell Cultures Ltd.
In an especially preferred version of the pharmaceutical agent the antibody is linked to a marker, especially to a fluorescent marker.
It is advantageous that the antibody can be detected with a high sensitivity and therefore only small amounts of the pharmaceutical means have to be applied for diagnosis. Additionally, the application of a pharmaceutical agent of this kind renders the diagnosis by means of automatic ELISA readers and flow cytometers possible.
Further advantages can be taken from the following description.
It is understood that the afore-mentioned features and those to be explained in the following can be used not only in the specific combination, but also in other combinations or alone without going beyond the scope of the present invention.
REFERENCES:
patent: 06141852A (1999-05-01), None
Harlow et al., “Labeling Antibodies”, in, Antibodies: A Laboratory Manual. Chapter 9, pp. 319-3358, Jan. 1988.*
Komatsu et al., Establishment and Characterization of a humna Leukemic cell line., Cancer Research, 51, 341-348, Jan. 1, 1991.*
Yoshida et al., Studies on natral ST2 gene products in the humna leukemic cell line UT-7 using monoclonal antihuman st2 antibodies., Hybridoma, vol. 14, No. 5, 1995.*
Wu et al., Indentification of IgG Fc receptor type II on humna megakaryoblastic cell lines., British Journal of Haematology, 1993, 84 pp.204-211.*
Takafuta et al., Expression of platelet membrane glycoprotein V in humna magakaryocytes and megakayocytic cell lines., Thromb. Haemostasis., 1994, 72(5), 762-769.*
Van den Oudenrijn et al., “Reactivity of the blind monoclonal antibody panel of the platelet section with megakaryocytic cell lines and cultured CD34 cells” Tissue Antigens-6th International workshop and conference on human leukocyte differentiation anti, Nov. 1996.*
Van Den Oudenrijn S. et al., “Reactivity of the Blind Monoclonal Antibody Panel of the Platelet Section With Megakaryocytic Cell Lines and Cultured CD34+Cells”Tissue Antigens-6th International Workshop and Conference on Human Leukocyte Differentiation Antigens, Bd. 48, Nr. 4-2, 10.—(Nov. 14, 1996) Kobe Japan.
Winderbank K. et al., Acute Megakaryocytic Leukemia (M7) in Childred,Mayo Clinical Proceedings, Bd. 64, Nr. 11, (1989) Seiten 1339-1351.
Chin Christopher L.
Cook Lisa V.
Eberhard-Karls-Universitat Tubingen Universitatsklinikum
Hamrick Claude A. S.
Oppenheimer Wolff & Donnelly LLP
LandOfFree
Antibody 97A6 does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antibody 97A6, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antibody 97A6 will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2584067